Tissue-specific aberrations of gene expression in HPRT-deficient mice: Functional complexity in a monogenic disease?

Molecular Therapy

Volumn 15, Issue 8, 2007, Pages 1432-1443

  Song, Shaochun ^a   Friedmann, Theodore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ANIMAL MODEL; ARTICLE; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG TARGETING; ENZYME DEFICIENCY; GENE EXPRESSION; GENE IDENTIFICATION; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSCRIPTION; HYPERURICEMIA; KNOCKOUT MOUSE; LESCH NYHAN SYNDROME; LIVER; MONOGENIC DISORDER; MOUSE; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; TISSUE SPECIFICITY; UNINDEXED SEQUENCE;

ANIMALS; GENE EXPRESSION REGULATION; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROTRANSMITTER AGENTS; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; PURINES; SIGNAL TRANSDUCTION;

MUS;

EID: 34547099559     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300199     Document Type: Article

References (49)

1. Jinnah, HA and Friedmann, T (2000). Lesch-Nyhan disease and its variants. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw Hill: New York. pp. 2537-2570.
2. Nyhan, WL, Oliver, WJ and Lesch, M (1965). A familial disorder or uric acid metabolism and central nervous system function II. J. Pediatr 67: 257-263.
3. Rosenbloom, FM, Kelley, WN, Miller, J, Henderson, JF and Seegmiller, JE (1967). Inherited disorder of purine metabolism. JAMA 202: 175-177.
4. Kelley, WN, Greene, ML, Rosenbloom, FM, Henderson, JF and Seegmiller, JE (1969). Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med 70: 155-206.
5. Harkness, RA, McCreanor, GM and Watts, RW (1988). Lesch-Nyhan syndrome and its pathogenesis: Purine concentrations in plasma and urine with metabolite profiles in CSF. J Inherit Metab Dis 11: 239-252.
6. Becker, MA and Roessler, BJ (1995). Hyperuricemia and gout. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill Book Company: New York. pp. 1192-1202.
7. Anderson, LT and Ernst, M (1994). Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 24: 67-81.
8. Davidson, BL, Tarle, SA, Van Antwerp, M, Gibbs, DA, Watts, RW, Kelley, WN et al. (1991). Identification of 17 independent mutations responsible for human hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Am J Hum Genet 48: 951-958.
9. Tarle, SA, Davidson, BL, Wu, VC, Zidar, FJ, Seegmiller, JE, Kelley, WN et al. (1991). Determination of the mutations responsible for the Lesch-Nyhan syndrome in 17 subjects. Genomics 10: 499-501.
10. Jinnah, HA, De Gregorio, L, Harris, JC, Nyhan, WL and O'Neill, JP (2000). The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res 463: 309-326.
11. Lloyd, KG, Hornykiewicz, O, Davidson, L, Shannak, K, Farley, I, Goldstein, M et al. (1981). Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Eng J Med 305: 1106-1111.
12. Breakefield, XO, Castiglione, CM and Edelstein, SB (1976). Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity. Science 192: 1018-1020.
13. Silverstein, FS, Johnston, MV, Hutchinson, RJ and Edwards, NL (1985). Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology 35: 907-911.
14. Breese, GR, Criswell, HE and Mueller, RA (1990). Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function. Prog NeuroPsychopharmacol Biol Psychiatry 14 (suppl.): S65-S80.
15. Jankovic, J, Caskey, TC, Stout, JT and Butler, IJ (1988). Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol 23: 466-469.
16. Ernst, M, Zametkin, AJ, Matochik, JA, Pascualvaca, D, Jons, PH, Hardy, K et al. (1996). Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 334: 1568-1572.
17. Yeh, J, Zheng, S and Howard, BD (1998). Impaired differentiation of HPRT-deficient dopaminergic neurons: A possible mechanism underlying neuronal dysfunction in Lesch-Nyhan syndrome. J Neurosci Res 53 78-85.
18. Wong, DF, Harris, JC, Naidu, S, Yokoi, F, Marenco, S, Dannals, RF et al. (1996). Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA 93: 5539-5543.
19. Breese, GR, Baumeister, AA, McCown, TJ, Emerick, SG, Frye, GD, Crotty, K et al. (1984). Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231: 343-354.
20. Breese, GR, Baumeister, AA, McCown, TJ, Emerick, SG, Frye, GD and Mueller, RA (1984). Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-multilation in the Lesch-Nyhan syndrome. Pharmacol Biochem Behav 21: 459-461.
21. Breese, GR, Criswell, HE, Johnson, KB, O'Callaghan, JP, Duncan, GE, Jensen, KF et al. (1994). Neonatal destruction of dopaminergic neurons. Neurotoxicology 15: 149-159.
22. Breese, GR, Duncan, GE, Napier, TC, Bondy, SC, Iorio, LC and Mueller, RA (1987). 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240: 167-176.
23. Erinoff, L and Snodgrass, SR (1986). Effects of adult or neonatal treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity, monoamine levels, and response to caffeine. Pharmacol Biochem Behav 24: 1039-1045.
24. Kuehn, MR, Bradley, A, Robertson, EJ and Evans, MJ (1987). A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326: 295-298.
25. Hoope, M, Hardy, K, Handyside, A, Hunter, S and Monk, M (1987). HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326: 292-295.
26. Dunnett, SB, Sirinathsinghji, DJ, Heavens, R, Rogers, DC and Kuehn, MR (1989). Monoamine deficiency in a transgenic (Hprt-) mouse model of Lesch-Nyhan syndrome. Brain Res 501: 401-406.
27. Finger, S, Heavens, RP, Sirinathsinghji, DJ, Kuehn, MR and Dunnett, SB (1988). Behavioral and neurochemical evaluation of a transgenic mouse model of Lesch-Nyhan syndrome. J Neurol Sci 86: 203-213.
28. Williamson, DJ, Sharkey, J, Clarke, AR, Jamieson, A, Arbuthnott, GW, Kelley, P et al. (1991). Analysis of forebrain dopaminergic pathways in HPRT-mice. Adv Exp Med Biol 309B: 269-272.
29. Jinnah, HA, Gage, FH and Friedmann, T (1990). Animal models of Lesch-Nyhan syndrome. Brain Res Bull 25: 467-475.
30. Jinnah, HA, Gage, FH and Friedmann, T (1991). Amphetamine-induced behavioral phenotype in a hypoxanthine-guanine phosphoribosyltransferase-deficient mouse model of Lesch-Nyhan syndrome. Behav Neurosci 105: 1004-1012.
31. Jinnah, HA, Hess, EJ, Wilson, MC, Gage, FH and Friedmann, T (1992). Localization of hypoxanthine-guanine phosphoribosyltransferase mRNA in the mouse brain by in situ hybridization. Mol Cell Neurosci 3: 64-78.
32. Jinnah, HA, Jones, MD, Wojcik, BE, Rothstein, JD, Hess, EJ, Friedmann, T et al. (1999). Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 72: 225-229.
33. Jinnah, HA, Langlais, PJ and Friedmann, T (1992). Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J Pharmacol Exp Ther 263: 596-607.
34. Jinnah, HA, Page, T and Friedmann, T (1993). Brain purines in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 60: 2036-2045.
35. Jinnah, HA, Wojcik, BE, Hunt, M, Narang, N, Lee, KY, Goldstein, M et al. (1994). Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci 14: 1164-1175.
36. Grunblatt, E, Mandel, S, Maor, G and Youdim, MB (2001). Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: Effect of R-apomorphine. J Neurochem 78: 1-12.
37. Subramaniam, A, Tamayo, P, Mootha, VK, Mukherjee, S, Ebert, BL, Gillette, MA et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
38. Smith, DW and Friedmann, T (2000). Characterization of the dopamine defect in primary cultures of dopaminergic neurons from hypoxanthine phosphoribosyltransferase knockout mice. Mol Ther 1: 486-491.
39. Bitler, CM and Howard, BD (1986). Dopamine metabolism in hypoxanthine-guanine phosphoribosyltransferase-deficient variants of PC12 cells. J Neurochem 47: 107-112.
40. Furnish, EJ, Zhou, W, Cunningham, CC, Kas, JA and Schmidt, CE (2001). Gelsolin overexpression enhances neurite outgrowth in PC12 cells. FEBS Lett 508: 282-286.
41. Messina, E, Micheli, V and Giacomello, A (2005). Guanine nucleotide depletion induces differentiation and aberrant neurite outgrowth in human dopaminergic neuroblastoma lines: A model for basal ganglia dysfunction in Lesch-Nyhan disease. Neurosci Lett 375: 97-100.
42. Mikolaenko, I, Rao, LM, Roberts, RC, Kolb, B and Jinnah, HA (2005). A Golgi study of neuronal architecture in a genetic mouse model for Lesch-Nyhan disease. Neurobiol Dis 20: 479-490.
43. Leegwater, PA, Vermeulen, G, Konst, AA, Naidu, S, Mulders, J, Visser, A et al. (2001). Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nature Genet 29: 358-359.
44. Bertelli, M, Cecchin, S, Lapucci, C, Jacomelli, G, Jinnah, HA, Pandolfo, M et al. (2006). Study of the adenosinergic system in the brain of HPRT knockout mouse (Lesch-Nyhan disease). Clin Chim Acta 373 104-107.
45. Zoref-Shani, E, Bromberg, Y, Brosh, S, Sidi, Y and Sperling, O (1993). Characterization of alterations in purine nucleotide metabolism in hypoxanthine-guanine phosphoribosyltransferase-deficient rat neuroma cell line. J Neurochem 61: 457-463.
46. Puig, JG, Jimenez, ML, Mateos, FA and Fox, IH (1989). Adenine nucleotide turnover in hypoxanthine-guanine phosphoribosyl-transferase deficiency: evidence for an increased contribution of purine biosynthesis de novo. Metabolism 38: 410-418.
47. Pinto, CS, Jinnah, HA, Shirley, TL, Nyhan, WL and Seifert, R (2005). Altered membrane NTPase activity in Lesch-Nyhan disease fibroblasts: comparison with HPRT knockout mice and HPRT-deficient cell lines. J Neurochem 93: 1579-1586.
48. Luthi-carter, R, Strand, A, Peters, NL, Solano, SM, Hollingsworth, ZR, Menon, AS et al. (2000). Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 22: 1259-1271.
49. Borovecki, F, Lovrecic, L, Zhou, J, Jeong, H, Then, F, Rosas, HD et al. (2005). Genome-wide expression profiling of human blood reveals biomarkers for Huntington's Disease. Proc Nat Acad Sci USA 102 11023-11028.